Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Human Resources | February 28, 2017 | March 02, 2017 |
| INVIVO THERAPEUTICS HOLDINGS CORP.NVIV · Entity 94539 | Director | January 19, 2018 | January 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,177 |
Ending reported balance
After 2017-02-28 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2017-02-28 · Exercise / conversion · Acquired 728 · Balance 4,665 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 2 · 2017-02-28 · Tax withholding · Disposed 335 · Balance 4,330 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 3 · 2017-02-28 · Exercise / conversion · Acquired 1,494 · Balance 5,824 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 4 · 2017-02-28 · Tax withholding · Disposed 485 · Balance 5,339 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 5 · 2017-02-28 · Exercise / conversion · Acquired 1,174 · Balance 6,513 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 6 · 2017-02-28 · Tax withholding · Disposed 553 · Balance 5,960 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 7 · 2017-02-28 · Exercise / conversion · Acquired 2,300 · Balance 8,260 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 8 · 2017-02-28 · Tax withholding · Disposed 1,083 · Balance 7,177 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-02-12 | Direct | 1,174 |
Reported balance
After 2017-02-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-02-28 · Other · Disposed 1,378 · Balance 1,174 F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-02-22 | Direct | 6,886 |
Reported balance
After 2017-02-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-02-28 · Other · Disposed 1,198 · Balance 6,886 F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-02-23 | Direct | 2,676 |
Reported balance
After 2017-02-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-02-28 · Other · Disposed 1,216 · Balance 2,676 F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-02-23 | Direct | 1,948 |
Reported balance
After 2017-02-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-02-28 · Exercise / conversion · Disposed 728 · Balance 1,948 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-02-22 | Direct | 5,392 |
Reported balance
After 2017-02-28 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-02-28 · Exercise / conversion · Disposed 1,494 · Balance 5,392 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F6: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-02-12 | Direct | 0 |
Reported balance
After 2017-02-28 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-02-28 · Exercise / conversion · Disposed 1,174 · Balance 0 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-02-12 | Direct | 1 |
Reported balance
After 2017-02-28 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-02-28 · Exercise / conversion · Disposed 2,300 · Balance 1 F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F10: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F11: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-02-12 | Direct | 0 |
Reported balance
After 2017-02-28 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-02-28 · Other · Disposed 1 · Balance 0 F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F11: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
F3: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F6: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F7: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
F8: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
F9: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
F10: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
F11: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
INVIVO THERAPEUTICS HOLDINGS CORP.
Report date January 19, 2018 · Filed January 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2028-01-19 | Direct | 12,500 |
Reported balance
After 2018-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-19 · Grant · Acquired 12,500 · Balance 12,500 F1: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 25,042 · Balance 0 F1: Includes 379 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 711,827 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 63,905 · Balance 0 F4: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 379 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023.
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 16:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 63,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090827 · ownership.xml · derivative · entry 3 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,905 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F4 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F4 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 711,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090827 · ownership.xml · derivative · entry 2 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 711,827 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 25,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090827 · ownership.xml · nonDerivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 379 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023. F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 17:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 63,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006692 · ownership.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,905 Underlying: Common Stock · 63,905 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-073306 · ownership.xml · derivative · entry 3 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,242 Underlying: Common Stock · 8,000 shares Expires 2029-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 8,000 | $41.45 | $331,608.00 |
DisclosureSEC source: 0000950170-23-073306 · ownership.xml · nonDerivative · entry 2 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,663 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.45 to $41.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 8,000 | $3.50 | $28,000.00 |
DisclosureSEC source: 0000950170-23-073306 · ownership.xml · nonDerivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 20:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 6,256 | $41.42 | $259,143.54 |
DisclosureSEC source: 0000950170-23-072377 · ownership.xml · nonDerivative · entry 2 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,663 F4 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 13,913 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072377 · ownership.xml · derivative · entry 3 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:24 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 13,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072377 · ownership.xml · nonDerivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Includes 2,736 shares previously acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:25 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 13,913 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004355 · doc4.xml · derivative · entry 2 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,913 Underlying: Common Stock · 13,913 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:25 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 54,749 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0000899243-23-004355 · doc4.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,749 Underlying: Common Stock · 54,749 shares Expires 2033-02-06 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:42 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 75,985 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005932 · doc4.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,985 Underlying: Common Stock · 75,985 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 175,438 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005095 · doc4.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,438 Underlying: Common Stock · 175,438 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 19:21 UTC | INVIVO THERAPEUTICS HOLDINGS CORP. NVIV · Entity 94539 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001179110-18-001034 · edgar.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-19 F1 · derivative.exercise_date: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 16 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 15 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 2,300 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F10 · shares: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). F10 · balance_after: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 14 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,174 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9 · shares: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F9 · derivative.underlying_shares: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F9 · balance_after: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,494 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 13 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 1,494 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8 · shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F8 · derivative.underlying_shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F8 · balance_after: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 728 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 12 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Underlying: Common Stock · 728 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F7 · balance_after: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 11 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 1,216 shares Expires 2018-02-23 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,198 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 10 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Underlying: Common Stock · 1,198 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,378 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 9 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,174 Underlying: Common Stock · 1,378 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,083 | $274.76 | $297,565.08 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 8 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,177 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 7 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 553 | $274.76 | $151,942.28 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 6 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 5 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 485 | $287.63 | $139,500.55 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 4 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,339 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 3 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 335 | $284.75 | $95,391.25 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 2 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 1 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:17 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007108 · form4.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380 Underlying: Common Stock · 6,380 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 18, 2017 Filed Jan 23, 2017 16:00 UTC | INVIVO THERAPEUTICS HOLDINGS CORP. NVIV · Entity 94539 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001179110-17-001169 · edgar.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-01-18 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.